Bicycle Therapeutics (BCYC) Net Income towards Common Stockholders (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Net Income towards Common Stockholders of -$60.8 million for Q1 2026, down 201.8% on a QoQ basis from -$20.2 million in Q4 2025, and little changed year-over-year from -$60.9 million in Q1 2025.
Bicycle Therapeutics (BCYC) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$60.8 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders changed 0.12% year-over-year to -$60.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$219.0 million (down 7.78% YoY) and the FY2025 annual result came in at -$219.0 million, down 29.54% from the prior year.
- Net Income towards Common Stockholders was -$60.8 million for Q1 2026 at Bicycle Therapeutics, down from -$20.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$20.2 million in Q4 2025 and bottomed at -$79.0 million in Q2 2025.
- A 5-year average of -$43.7 million and a median of -$42.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 61.13% in 2025, while the deepest fall reached 128.72% in 2025.
- Bicycle Therapeutics' Net Income towards Common Stockholders stood at -$30.0 million in 2022, then plunged by 63.78% to -$49.1 million in 2023, then declined by 5.61% to -$51.9 million in 2024, then surged by 61.13% to -$20.2 million in 2025, then sank by 201.8% to -$60.8 million in 2026.
- Business Quant data shows BCYC's Net Income towards Common Stockholders at -$60.8 million in Q1 2026, -$20.2 million in Q4 2025, and -$59.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | -0.68 |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - | -453.82 Mn |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -60.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.83 Mn |
| Dec 31, 2025 | -20.15 Mn |
| Sep 30, 2025 | -59.10 Mn |
| Jun 30, 2025 | -78.95 Mn |
| Mar 31, 2025 | -60.75 Mn |
| Dec 31, 2024 | -51.85 Mn |
| Sep 30, 2024 | -50.80 Mn |
| Jun 30, 2024 | -39.81 Mn |
| Mar 31, 2024 | -26.56 Mn |
| Dec 31, 2023 | -49.10 Mn |
| Sep 30, 2023 | -49.90 Mn |
| Jun 30, 2023 | -42.60 Mn |
| Mar 31, 2023 | -39.06 Mn |
| Dec 31, 2022 | -29.98 Mn |
| Sep 30, 2022 | -28.35 Mn |
| Jun 30, 2022 | -26.83 Mn |
| Mar 31, 2022 | -27.56 Mn |
| Dec 31, 2021 | -18.04 Mn |
| Sep 30, 2021 | -14.68 Mn |
| Jun 30, 2021 | -17.91 Mn |